Primary tolerability end points ( administration-site observations , systemic adverse events [ AEs ] , and subject-assessed pain ) were assessed , and pharmacokinetic parameters ( AUC , Cmax , Tmax , t ) were computed to compare relative rate and extent of systemic exposure .